Innocutis

Innocutis is a biopharmaceutical company focused on developing and commercializing innovative dermatological treatments. The company operates to enhance the quality of life for patients suffering from various skin conditions. Founded in 2010 in Charleston, US, Innocutis specializes in dermatological products. The company was acquired by Cipher Pharmaceuticals in April 2015 for USD 45.

5 mn, marking a significant milestone in its corporate journey. Innocutis provides a range of dermatological products designed to address skin ailments. Their offerings include prescription treatments for various skin conditions, tailored for both healthcare providers and patients. The company primarily serves the North American market while exploring potential international expansion opportunities.

Innocutis generates its revenue via a model that involves direct sales of its prescription dermatological products. This structure allows for a steady income flow, with sales occurring directly between Innocutis and healthcare providers or pharmacies, ensuring a straightforward B2B relationship. Innocutis plans to expand its product line by developing new dermatological treatments aimed at underserved skin conditions. The company is also targeting international markets for expansion, particularly in regions experiencing rising demand for specialized skincare solutions.

The recent acquisition by Cipher Pharmaceuticals will support these initiatives, providing the necessary resources for innovation and market entry.